HCA Healthcare, Inc.
No SEC Form 4 filings for $HCA in the last 30 days.
See all $HCA insider activity →HCA Healthcare (HCA) reduced its 2026 profit outlook, citing a weaker payer mix that decreased quarterly revenue by $400 million. A Pomerantz fraud investigation adds scrutiny. Shares fell 3.07% in 7 days, 2.02% in 30 days, despite a 12.09% gain in 90 days and 51.53% over 3 years. Analysts debate its valuation, with a fair value estimate of $458.67, above the recent $405.00 close.
HCA Healthcare (HCA) cut its 2026 profit outlook, citing a shift to more uninsured patients, rising costs, and softer elective surgeries, expecting a $1.00–$1.20 billion pretax income impact. The company is reducing roles and exiting assets, while facing an investor probe. Management now expects diluted EPS of $28.70–$30.50 for 2026, down from prior estimates.
Tenet Healthcare (THC) has outperformed HCA Healthcare with a 32.3% YTD gain and 40.7% 52-week increase. Analysts rate HCA a 'Moderate Buy' with a mean price target of $455.05, implying 12% upside.
Over the past 7 days, alphai's AI scored 6 news stories mentioning HCA (HCA Healthcare, Inc.). Coverage has skewed bearish: 2 bullish, 0 neutral, and 4 bearish.
Recent HCA coverage spans financial news, earnings and regulation.
Guidance cut and fraud probe likely pressure HCA stock lower in the short term.
Guidance downgrade signals margin pressure and may trigger short‑term price weakness.
The new consensus rating and price target suggest modest upside potential.
Potential legal liability and reputational risk for HCA.
Potential network exit could reduce patient volume and reimbursements for HCA in Alaska.
alphai scores every news story that mentions HCA with an AI model for sentiment and relevance, and aggregates insider trades from HCA Healthcare, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HCA Healthcare (HCA) reduced its 2026 profit outlook, citing a weaker payer mix that decreased quarterly revenue by $400 million. A Pomerantz fraud investigation adds scrutiny. Shares fell 3.07% in 7 days, 2.02% in 30 days, despite a 12.09% gain in 90 days and 51.53% over 3 years. Analysts debate its valuation, with a fair value estimate of $458.67, above the recent $405.00 close.
2 min readHCA Healthcare (HCA) cut its 2026 profit outlook, citing a shift to more uninsured patients, rising costs, and softer elective surgeries, expecting a $1.00–$1.20 billion pretax income impact. The company is reducing roles and exiting assets, while facing an investor probe. Management now expects diluted EPS of $28.70–$30.50 for 2026, down from prior estimates.
2 min readTenet Healthcare (THC) has outperformed HCA Healthcare with a 32.3% YTD gain and 40.7% 52-week increase. Analysts rate HCA a 'Moderate Buy' with a mean price target of $455.05, implying 12% upside.
1 min readA class action lawsuit against HCA Healthcare alleges patients had to accept cookies to book urgent care appointments online, sharing personal and health data with Google. The plaintiffs claim this violates Tennessee HIPAA laws. HCA disputes the claims and plans to defend itself. Cyber experts recommend using VPNs and other protections to safeguard personal data.
2 min readPremera Blue Cross of Alaska and HCA Healthcare, owner of Alaska Regional Hospital, are in a contract dispute. If unresolved, the hospital may leave Premera's network on Oct. 1, 2026, affecting in-network access for Premera members. Both parties are negotiating, but no agreement has been reached yet. According to Premera, it seeks fair compensation for providers while maintaining affordability for Alaskans. HCA has not publicly responded to Premera's claims. If the dispute is not resolved, Preme
2 min readMichael Burry, known for his 'Big Short' bet, disclosed August trades including long positions in MercadoLibre (MELI), Zoetis (ZTS), Lululemon (LULU), and Molina Healthcare (MOH), and short positions in Palantir (PLTR), Nvidia (NVDA), and others. Nine of his 17 long holdings rose, with Veeva (VEEV) up 35.8%, while his short bets faced pressure as AI stocks rallied, with Palantir up 51.4%. Burry adjusted his portfolio, raising cash and managing risk.
3 min readHCA Healthcare (HCA) filed a Form 4 with the SEC, detailing insider transactions. EVP Michael R. McAlevey sold 7,769 shares at $429 each, with holdings adjusted across various trusts. The transactions did not change total beneficial ownership. Prices were based on the average of high and low shares on the transaction date.
1 min readHCA Healthcare has acquired and now operates the urgent care clinic formerly known as Texas MedClinic in New Caney, Texas. The company began managing all Texas MedClinic locations on August 1, offering services like X-rays, lab testing, and COVID-19 testing.
1 min readHCA Healthcare's analyst ratings have shifted to a more bearish stance. JPMorgan reduced its price target to $425, citing a revised financial model. The mean target is $453.45, implying an 11.6% premium, while the highest target is $579, suggesting a 42.5% upside.
1 min readHCA Healthcare reported Q2 2026 revenue of $20.23B, beating estimates. Earnings were $7.59 per share, up from $6.84 in the same quarter last year. Westpac acquired a new stake worth $4.648M. The company declared a $0.78 quarterly dividend. Analysts have mixed views on the stock, with a Moderate Buy consensus and an average price target of $462.64.
2 min read
